Osteoporosis Intermittent dosing drives market growth

Introduction

The long-standing unmet need of the osteoporosis market has been for improved adherence to treatment. Two pipeline products, Amgen's Denosumab and Novartis' Aclasta (zoledronate), have answered this demand with intermittent dosing schedules and consequently are expected to generate blockbuster revenues. This will rejuvenate the market which is otherwise stalling under multiple patent expiries.

Scope of this report

Analysis of patient potential, unmet needs and clinical trial design in osteoporosis

Overview of drugs in late- and early-stage clinical development; with analysis of key companies involved in the R&D pipeline

Detailed profiles of key compounds in development for use in osteoporosis, with forecasts of drug revenues to 2016

Review of the key strategies adopted by current market players

Research and analysis highlights

Despite the genericization of the market leader Fosamax and patent expiries on other key brands, pipeline products are still viable. Datamonitor expects pipeline products to swell the total market value 4.4% between 2007 and 2016 to $10.9 billion.

Products that offer intermittent dosing schedules are highly desirable in the osteoporosis market and can generate blockbuster revenues. Such therapies answer the demand from patients and physicians for more convenient delivery mechanisms that increase compliance and ultimately improve treatment outcome.

Although bisphosphonates are the mainstay of osteoporosis treatment, there is potential for new and innovative products to gain market share. Those that suit niche populations, such as Amgen's ED-71 which finds favor as a vitamin D analogue in Japan, will be able to fight generic competition.

Key reasons to read this report

Understand clinical and environmental unmet needs in the osteoporosis market based on key opinion leader comments

Benchmark key late-stage pipeline products against the current market leader and class comparator

Assess the global (US, Japan, five major EU) sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential

Published: 30 March 2007

PDF Format
Table of Contents
Price: $11,400.00 / GBP5,700.00